Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-25T10:14:06.225Z Has data issue: false hasContentIssue false
  • English
  • Français

Use of selective serotonin and norepinephrine reuptake inhibitors (SNRIs) in the treatment of autism spectrum disorder (ASD), comorbid psychiatric disorders and ASD-associated symptoms: a clinical review

Published online by Cambridge University Press:  07 December 2020

Muralidhara Shankarapura Nanjappa ,
Emanuel Voyiaziakis ,
Basant Pradhan  and
Srinagesh Mannekote Thippaiah Open the ORCID record for Srinagesh Mannekote Thippaiah [Opens in a new window]
Muralidhara Shankarapura Nanjappa
Affiliation:
Child and Adolescent Psychiatry, Park Nicollet Specialty Center, Saint Louis Park, Minnesota, USA
Emanuel Voyiaziakis
Affiliation:
Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Glen Oaks, New York, USA
Basant Pradhan
Affiliation:
Psychiatry and Pediatrics, Cooper Medical School of Rowan University, Camden, New Jersey, USA
Srinagesh Mannekote Thippaiah*
Affiliation:
Psychiatry, Creighton University School of Medicine-Phoenix Campus Valley wise Behavioral Health CenterPhoenixAZ
*
*Author for correspondence: Srinagesh Mannekote Thippaiah, MD, FAP, FAM, Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

It is challenging to treat symptoms of autism spectrum disorder (ASD), comorbid psychiatric disorders and ASD-associated symptoms. Some of the commonly used medications to treat these can, and frequently do have serious adverse side effects. Therefore, it is important to identify medications that are effective and with fewer side effects and negative outcomes. In this review, we looked at current evidence available for using the serotonin and norepinephrine reuptake inhibitors (SNRIs) class of medications in treating some of these often difficult to treat symptoms and behaviors. An extensive literature search was conducted using EBSCO.host. Our search algorithm identified 130 articles, 6 of which were deemed to meet criteria for the purpose of this review. Each of these six articles was independently reviewed and critically appraised. As a prototype of the SNRIs family, venlafaxine was found to be a useful adjuvant in children and adults with ASD for the treatment of self-injurious behaviors, aggression, and ADHD symptoms when used in doses lower than its antidepressant dosage. However, duloxetine was not found to show any added benefit in treatment of any of the comorbid symptoms and behaviors in ASD when compared to other antidepressants. On the other hand, milnacipran was reported to produce improvements in impulsivity, hyperactivity symptoms, and social functioning through reduction of inattention of ADHD when comorbid with ASD. Overall, SNRIs were shown variable effectiveness in treatment of these comorbid symptoms and behaviors in ASD.

Keywords

Autismautistic spectrum disorderpervasive developmental disorderSNRIsvenlafaxinedesvenlafaxineduloxetinemilnacipran
Type
Review
Information
CNS Spectrums , Volume 27 , Issue 3 , June 2022 , pp. 290 - 297
Copyright
© The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

DSM5. DSM (Diagnostic and Statistical Manual of Mental Disorders). 5th ed. . Washington, DC: APA; 2013.Google Scholar
Rice, CE, Baio, J, Van Naarden, BK, Doernberg, N, Meaney, FJ, Kirby, RS. A public health collaboration for the surveillance of autism spectrum disorders. Paediatr Perinat Epidemiol. 2007;21(2):179–190.CrossRefGoogle ScholarPubMed
CDC. Autism prevalence slightly higher in CDC’s ADDM Network. https://www.cdc.gov/media/releases/2018/p0426-autism-prevalence.html. Accessed April 26, 2018.Google Scholar
Brereton, AV, Tonge, BJ, Einfeld, SL. Psychopathology in children and adolescents with autism compared to young people with intellectual disability. J Autism Dev Disord. 2006;36(7):863–870.CrossRefGoogle ScholarPubMed
Matson, JL, Rivet, TT. Characteristics of challenging behaviours in adults with autistic disorder, PDD-NOS, and intellectual disability. J Intellect Dev Disabil. 2008;33(4):323–329.CrossRefGoogle ScholarPubMed
Kanne, SM, Mazurek, MO. Aggression in children and adolescents with ASD: prevalence and risk factors. J Autism Dev Disord. 2011;41(7):926–937.CrossRefGoogle ScholarPubMed
Soke, GN, Rosenberg, SA, Hamman, RF, et al. Brief report: prevalence of self-injurious behaviors among children with autism spectrum disorder-a population-based study. J Autism Dev Disord. 2016;46(11):3607–3614.CrossRefGoogle ScholarPubMed
Matson, JL, Dempsey, T, Fodstad, JC. Stereotypies and repetitive/restrictive behaviours in infants with autism and pervasive developmental disorder. Dev Neurorehabil. 2009;12(3):122–127.CrossRefGoogle ScholarPubMed
Leitner, Y. The co-occurrence of autism and attention deficit hyperactivity disorder in children—what do we know? Frontiers in human neuroscience. 2014;8:268–268.CrossRefGoogle ScholarPubMed
Molteni, M, Nobile, M, Cattaneo, D, Radice, S, Clementi, E. Potential benefits and limits of psychopharmacological therapies in pervasive developmental disorders. Curr Clin Pharmacol. 2014;9(4):365–376.CrossRefGoogle ScholarPubMed
Fung, LK, Mahajan, R, Nozzolillo, A, et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics. 2016;137(Suppl 2):S124–S135.CrossRefGoogle ScholarPubMed
Barnard, L, Young, AH, Pearson, J, Geddes, J, O’Brien, G. A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol. 2002;16(1):93–101.10.1177/026988110201600113CrossRefGoogle ScholarPubMed
Vasa, RA, Carroll, LM, Nozzolillo, AA, et al. A systematic review of treatments for anxiety in youth with autism spectrum disorders. J Autism Dev Disord. 2014;44(12):3215–3229.CrossRefGoogle ScholarPubMed
Steingard, R, Zimnitzky, B, Demaso, D, Bauman, M, Bucci, J. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol. 1997;7:9–15.CrossRefGoogle ScholarPubMed
McPheeters, ML, Warren, Z, Sathe, N, et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics. 2011;127(5):e1312–e1321.CrossRefGoogle ScholarPubMed
Schatzberg, AF. New indications for antidepressants. J Clin Psychiatry. 2000;61(suppl 11):9–17.Google ScholarPubMed
Dhaliwal, JS, Molla, M. Duloxetine. In: StatPearls. Treasure Island, FL: StatPearls Publishing LLC.: 2019.Google Scholar
English, C, Rey, JA, Rufin, C. Milnacipran (Savella), a treatment option for fibromyalgia. Pharm Therapeut. 2010;35(5):261–266.Google Scholar
Pae, C-U, Marks, DM, Shah, M, et al. Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol. 2009;32(6):355–363.CrossRefGoogle ScholarPubMed
Li, F, Tsien, JZ. Memory and the NMDA receptors. N Engl J Med. 2009;361(3):302–303.CrossRefGoogle ScholarPubMed
Hurwitz, R, Blackmore, R, Hazell, P, Williams, K, Woolfenden, S. Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents. Cochrane Database Syst Rev. 2012;3:Cd008372.Google Scholar
Higashino, K, Ago, Y, Umehara, M, et al. Effects of acute and chronic administration of venlafaxine and desipramine on extracellular monoamine levels in the mouse prefrontal cortex and striatum. Eur J Pharmacol. 2014;729:86–93.CrossRefGoogle ScholarPubMed
Green, SA, Rudie, JD, Colich, NL, et al. Overreactive brain responses to sensory stimuli in youth with autism spectrum disorders. J Am Acad Child Adolesc Psychiatry. 2013;52(11):1158–1172.CrossRefGoogle ScholarPubMed
Zald, DH. The human amygdala and the emotional evaluation of sensory stimuli. Brain Res Brain Res Rev. 2003;41(1):88–123.CrossRefGoogle ScholarPubMed
Stein, JL, Wiedholz, LM, Bassett, DS, et al. A validated network of effective amygdala connectivity. Neuroimage. 2007;36(3):736–745.CrossRefGoogle ScholarPubMed
Maia, TV, Cooney, RE, Peterson, BS. The neural bases of obsessive-compulsive disorder in children and adults. Dev Psychopathol. 2008;20(4):1251–1283.CrossRefGoogle ScholarPubMed
Milad, MR, Rauch, SL. Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn Sci. 2012;16(1):43–51.CrossRefGoogle ScholarPubMed
Wright, P, Albarracin, D, Brown, RD, Li, H, He, G, Liu, Y. Dissociated responses in the amygdala and orbitofrontal cortex to bottom-up and top-down components of emotional evaluation. Neuroimage. 2008;39(2):894–902.CrossRefGoogle ScholarPubMed
Green, SA, Hernandez, L, Tottenham, N, Krasileva, K, Bookheimer, SY, Dapretto, M. Neurobiology of sensory overresponsivity in youth with autism spectrum disorders. JAMA Psychiatry. 2015;72(8):778–786.CrossRefGoogle ScholarPubMed
Sladky, R, Höflich, A, Küblböck, M, et al. Disrupted effective connectivity between the amygdala and orbitofrontal cortex in social anxiety disorder during emotion discrimination revealed by dynamic causal modeling for FMRI. Cereb Cortex. 2015;25(4):895–903.CrossRefGoogle ScholarPubMed
Miller, CW, Hodzic, V, Weintraub, E. Current understanding of the neurobiology of agitation. Western J Emergency Med. 2020;21(4):841–848.CrossRefGoogle ScholarPubMed
Siever, LJ. Neurobiology of aggression and violence. Am J Psychiatry. 2008;165(4):429–442.CrossRefGoogle ScholarPubMed
London, EB. Neuromodulation and a reconceptualization of autism spectrum disorders: using the locus coeruleus functioning as an exemplar. Front Neurol. 2018;9:1120.CrossRefGoogle Scholar
Ming, X, Gordon, E, Kang, N, Wagner, GC. Use of clonidine in children with autism spectrum disorders. Brain Dev. 2008;30(7):454–460.CrossRefGoogle ScholarPubMed
Pavăl, D. A dopamine hypothesis of autism spectrum disorder. Dev Neurosci. 2017;39(5):355–360.CrossRefGoogle ScholarPubMed
Kriete, T, Noelle, DC. Dopamine and the development of executive dysfunction in autism spectrum disorders. PLoS One. 2015;10(3):e0121605.CrossRefGoogle ScholarPubMed
Ellingrod, VL, Perry, PJ. Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm. 1994;51(24):3033–3046.Google ScholarPubMed
Baxter, AJ, Charlson, FJ, Cheng, HG, Shidhaye, R, Ferrari, AJ, Whiteford, HA. Prevalence of mental, neurological, and substance use disorders in China and India: a systematic analysis. Lancet Psychiatry. 2016;3(9):832–841.CrossRefGoogle ScholarPubMed
Locher, C, Koechlin, H, Zion, SR, et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74(10):1011–1020.CrossRefGoogle ScholarPubMed
Hollander, E, Kaplan, A, Cartwright, C, Reichman, D. Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. J Child Neurol. 2000;15:132–135.CrossRefGoogle Scholar
Carminati, GG, Deriaz, N, Bertschy, G. Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit/hyperactivity disorders (ADHD)-like symptoms. Progr Neuro-Psychopharmacol Biol Psychiatry. 2006;30(2):312–315.CrossRefGoogle Scholar
Carminati, GG, Gerber, F, Darbellay, B, et al. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2016;65:85–95.CrossRefGoogle ScholarPubMed
Nielderhofer, H. Efficacy of duloxetine and agomelatine does not exceed that of other antidepressants in patients with autistic disorder: preliminary results in 3 patients. Primary Care Companion CNS Disord. 2011;13(1):PCC.10l01038.Google Scholar
Mashiko, H, Ishikawa, H, Itagaki, S, et al. Milnacipran for attention-deficit hyperactivity disorder symptoms in adult asperger’s disorder. Open J Psychiatry. 2014;4(03):195.CrossRefGoogle Scholar
Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism. 2020. https://ClinicalTrials.gov/show/NCT01337700.Google Scholar
Simonoff, E, Pickles, A, Charman, T, Chandler, S, Loucas, T, Baird, G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry. 2008;47(8):921–929.CrossRefGoogle Scholar
Madden, JM, Lakoma, MD, Lynch, FL, et al. Psychotropic medication use among insured children with autism spectrum disorder. J Autism Dev Disord. 2017;47(1):144–154.CrossRefGoogle ScholarPubMed
Golubchik, P, Sever, J, Weizman, A. Reboxetine treatment for autistic spectrum disorder of pediatric patients with depressive and inattentive/hyperactive symptoms: an open-label trial. Clin Neuropharmacol. 2013;36(2):37–41.CrossRefGoogle Scholar
Williams, K, Wheeler, DM, Silove, N, Hazell, P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2010;8:Cd004677.CrossRefGoogle Scholar
Singh, K, Connors, SL, Macklin, EA, et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci USA. 2014;111(43):15550–15555.CrossRefGoogle Scholar
Stepanova, E, Dowling, S, Phelps, M, Findling, RL. Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents. Dialog Clin Neurosci. 2017;19(4):395–402.CrossRefGoogle ScholarPubMed
Calarge, CA, Acion, L, Kuperman, S, Tansey, M, Schlechte, JA. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol. 2009;19(2):101–109.CrossRefGoogle ScholarPubMed
Ward, F, Nanjappa, M, Hinder, SAJ, Roy, M. Use of melatonin for sleep disturbance in a large intellectual disability psychiatry service. Int J Dev Disabil. 2015;61(3):182–187.CrossRefGoogle Scholar
Strawn, JR, Prakash, A, Zhang, Q, et al. A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. J Am Acad Child Adol Psychiatry. 2015;54(4):283–293.CrossRefGoogle ScholarPubMed
Noone, RCF, Taylor, B, Racine, E, Hollander, E. Milnacipran vs. placebo in adult autism spectrum disorder: impact on hyperactivity/impulsivity domain Neuropsychopharmacology. 2014;39(Suppl 1):S291–S472.Google Scholar